Search research articles
Contact Us
Filters
Showing results (11-20 of 49) with videos related to
Page
of 5
Sort By:
Cardiovascular Drugs and Therapy
|
March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study
Leslie Cho, Michael Rocco, David Colquhoun, et al.
Clinical Cardiology
|
January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy
Leslie Cho, Michael Rocco, David Colquhoun, et al.
Journal of Cardiovascular Pharmacology
|
July 21, 2015
Systemic Glucocorticoids Are Associated With Mortality After Carotid Endarterectomy
Marten Siemelink, Hester den Ruijter, Fleur van der Valk, et al.
Journal of the American Heart Association
|
September 15, 2016
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Erik Stroes, John R Guyton, Norman Lepor, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 15, 2007
Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma
Houshang Monajemi, Lin Zhang, Gang Li, et al.
Cardiology and Therapy
|
June 22, 2020
A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
Michael J Koren, Peter H Jones, Jennifer G Robinson, et al.
Plos One
|
March 4, 2014
The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial
Fleur van der Valk, Carlijne Hassing, Maartje Visser, et al.
Journal of Comparative Effectiveness Research
|
June 19, 2026
Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison
Handrean Soran, Asia Sikora Kessler, Montserrat Vera-Llonch, et al.
Cardiovascular Research
|
August 31, 2018
From design to the clinic: practical guidelines for translating cardiovascular nanomedicine
Iwona Cicha, Cédric Chauvierre, Isabelle Texier, et al.
Journal of the American College of Cardiology
|
April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
Erik Stroes, David Colquhoun, David Sullivan, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 49) with videos related to
Sort By:
Page
of 5
Cardiovascular Drugs and Therapy
|
March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study
Leslie Cho, Michael Rocco, David Colquhoun, et al.
Clinical Cardiology
|
January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy
Leslie Cho, Michael Rocco, David Colquhoun, et al.
Journal of Cardiovascular Pharmacology
|
July 21, 2015
Systemic Glucocorticoids Are Associated With Mortality After Carotid Endarterectomy
Marten Siemelink, Hester den Ruijter, Fleur van der Valk, et al.
Journal of the American Heart Association
|
September 15, 2016
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Erik Stroes, John R Guyton, Norman Lepor, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 15, 2007
Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma
Houshang Monajemi, Lin Zhang, Gang Li, et al.
Cardiology and Therapy
|
June 22, 2020
A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
Michael J Koren, Peter H Jones, Jennifer G Robinson, et al.
Plos One
|
March 4, 2014
The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial
Fleur van der Valk, Carlijne Hassing, Maartje Visser, et al.
Journal of Comparative Effectiveness Research
|
June 19, 2026
Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison
Handrean Soran, Asia Sikora Kessler, Montserrat Vera-Llonch, et al.
Cardiovascular Research
|
August 31, 2018
From design to the clinic: practical guidelines for translating cardiovascular nanomedicine
Iwona Cicha, Cédric Chauvierre, Isabelle Texier, et al.
Journal of the American College of Cardiology
|
April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
Erik Stroes, David Colquhoun, David Sullivan, et al.
Page
of 5